Statement Of Cash Flows [Abstract]

OSE Immunotherapeutics - Filing #831399

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations
18 714 EUR
14 874 EUR
Income taxes paid (refund), classified as operating activities
0 EUR
0 EUR
Cash flows from (used in) operating activities
19 764 EUR
18 252 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
507,000 EUR
26,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
11 357 EUR
0 EUR
Proceeds from borrowings, classified as financing activities
5 023 EUR
12 056 EUR
Repayments of borrowings, classified as financing activities
2 719 EUR
1 010 EUR
Payments of lease liabilities, classified as financing activities
637,000 EUR
785,000 EUR
Interest paid, classified as financing activities
0 EUR
0 EUR
Other inflows (outflows) of cash, classified as financing activities
0 EUR
0 EUR
Cash flows from (used in) financing activities
13 324 EUR
10 267 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
0 EUR
0 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
6 948 EUR
7 959 EUR
Cash and cash equivalents
18 672 EUR
25 620 EUR
33 579 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.